NCT01560741.

Methods	Study design: unknown centres; double‐blinded, parallel individual randomised controlled trial in Portugal Duration: 36 weeks Setting: hospital
Participants	Population: 128 adults recruited from Portugal Baseline characteristics: unknown Inclusion criteria: < 80 years of age, PaCO₂ > 45 mmHg, IMC > 40 kg/m², LTOT for at least 3 months, 1 exacerbation in last year, FEV₁ < 50%predicted, FEV₁/FVC < 60%, TLC > 90% predicted, GOLD guidelines therapy, pH > 7.35, free of exacerbations 4 weeks before recruitment Exclusion criteria: OHS: COPD, NMD; COPD: 15% increase in FEV₁ after inhaled salbutamol (200 μg), actively smoking, history of OSA; NMD and CWD: COPD; OHS; PCF < 270; MIC/VC = 1, severe bulbar weakness
Interventions	Measurements taken at baseline, at 12 weeks, and at end of study Treatment arms Remote monitoring while patient sleeps utilising non‐invasive equipment UC to receive equipment after study period
Outcomes	Primary outcomes: difference of 1 hour in the mean of nightly hours of use Secondary outcomes: QOL, health economics, arterial blood gases
Notes	Funding: Hospital Sao Joao Other identifier:NCT01560741; TeleMotiNIV2012